Today: 18 July 2026
Browse Category

Biotechnology 31 October 2025 - 10 November 2025

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor, sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival of 16.5 months vs. 9.2 months for sunitinib alone and a 46% objective response rate vs. 26% on sunitinib monotherapy. GlobeNewswire
10 November 2025
···
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Ethos Financial Group’s new position adds to a year when institutions already control roughly three‑quarters of the float. MarketBeat’s automated brief also captures the latest insider activity, and a blended “Moderate Buy” Street view. While 13F adds don’t guarantee direction, they often increase visibility ahead of catalysts. MarketBeat
9 November 2025
·
Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

Tenaya Therapeutics presented new interim results from its MyPEAK‑1 Phase 1b/2a trial evaluating TN‑201, an AAV9 gene‑replacement therapy designed to deliver a working MYBPC3 gene to cardiomyocytes for MYBPC3‑associated hypertrophic cardiomyopathy. The late‑breaking presentation in New Orleans highlighted longer‑term follow‑up for the first‑dose cohort and initial readouts at the higher dose, with a simultaneous publication in Cardiovascular Research. GlobeNewswire
8 November 2025
·
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran, its in vivo CRISPR therapy for transthyretin amyloidosis. The FDA’s clinical holds on MAGNITUDE and MAGNITUDE‑2 are still in effect pending a formal hold letter. GlobeNewswire+1
7 November 2025
···
Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics, Inc. reported third‑quarter 2025 results this morning, highlighting sequential revenue growth, materially higher gross margins, and steady commercial momentum for its tumor‑infiltrating lymphocyte therapy Amtagvi. Management also reaffirmed full‑year revenue guidance and flagged pipeline milestones led by encouraging lung‑cancer data for lifileucel. GlobeNewswire
6 November 2025
···
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax, Inc. reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion. Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the outlook. The company also reaffirmed 2025 operating‑expense guidance. ir.novavax.com
6 November 2025
·····
From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company pioneering an unusual dual focus: AI-driven drug discovery and biodefense. The company’s mission is to “capture biological signals at scale, decode them with AI, and rapidly validate insights in model systems”, bridging cutting-edge computation with experimental biotechainvest.comainvest.com. In practical terms, Lunai is developing both therapeutic platforms and advanced diagnostics/screening tools, all underpinned by machine learning.
5 November 2025
···
‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

Europe’s HOBI‑WAN pilot is ESA’s clearest sign yet that microbial food production will be part of living off‑Earth. The agency says the demonstrator feeds a bacterial culture with stored gases to produce Solein, a protein‑rich powder that needs “neither farmland nor sunlight.” The ISS testbed will ride in a standard locker and includes safety‑critical gas‑injection cartridges because hydrogen/oxygen handling in microgravity must be fail‑safe. The first eight months build and validate a ground “science model,” then ESA aims to manufacture, test and launch a flight unit. European Space Agency
5 November 2025
····
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis is the global frontrunner in animal health, offering a diverse portfolio for both companion animals and farm animals. The company’s products range from vaccines and parasiticides to dermatology treatments and high-tech diagnostics. This breadth has helped Zoetis capture the #1 industry position – in 2023 its $8.5B in sales exceeded the next-largest competitor by over 50%proclinical.comproclinical.com. Zoetis continues to leverage this scale and innovation engine in 2025, focusing on pet care growth while managing challenges in livestock.
4 November 2025
··
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta (SRPT) Stock Collapses 80% on FDA Bombshell – Is a Big Rebound Coming?

Sarepta’s stock has experienced a dramatic collapse in 2025, wiping out years of gains. After starting the year near all-time highs, SRPT shares have plunged by over 80% year-to-datemarketbeat.com. As of early November 2025, the stock trades in the mid-teens, down from about $120–$130 at the start of the year. In fact, the stock’s 52-week range tells the story: it hit a high of $138.81 and a low of just $10.41 over the past yearmarketbeat.com. This implosion has vastly underperformed the biotech sector and the broader market.
4 November 2025
··
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technologyphiopharma.com. Originally known as RXi Pharmaceuticals, Phio rebranded and refocused on immuno-oncology. Its mission is to use small interfering RNA to “silence” genes that allow tumors to evade the immune system, thereby empowering the body’s own defenses to fight cancerragingbull.com.
3 November 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch in late September when Phase 1/2 trial data showed a remarkable 75% reduction in disease progression with AMT-130 – news that caused the stock to surge almost 200% that monthreuters.com. By late October, QURE was hovering around $68–$70, up roughly 300–500% from spring levels.
3 November 2025
··
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics is a Boston-area biotech founded in 2018, emerging with a mission to revolutionize cancer treatment through precision medicinestockanalysis.com. The company’s name “Acrivon” is derived from “accurate” or “precision,” reflecting its core approach: develop targeted oncology drugs hand-in-hand with diagnostics that pinpoint the patients who will respond. Acrivon’s proprietary platform, AP3, lies at the heart of this strategy. Using proteomics and AI tools, AP3 measures the activity of myriad proteins and signaling pathways inside tumor cells in their native state, rather than just analyzing DNA mutationsglobenewswire.comglobenewswire.com. This allows Acrivon to create drug-specific “OncoSignature” tests – essentially companion diagnostics that predict whether a patient’s tumor is susceptible to a given drugstockanalysis.comstockanalysis.com. It’s a novel twist on precision oncology: instead of the traditional focus on genetic markers, Acrivon’s proteomic signatures aim to capture real-time tumor biology to guide therapynasdaq.comglobenewswire.com.
3 November 2025
··
Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou Biosciences – a clinical-stage biotech focusing on genome-edited cell therapies – stunned the biotech world with new data on November 3, 2025, showcasing that its off-the-shelf CAR-T cell treatments can achieve remission rates on par with personalized CAR-T therapiesstatnews.com. In an early-morning webcast, Caribou revealed Phase 1 trial outcomes from two programs: vispa-cel for B-cell lymphoma and CB-011 for multiple myelomatipranks.com. The headline: patients with aggressive blood cancers, who had exhausted other options, responded remarkably well to these donor-derived CAR-T infusions. Caribou reported multiple complete and durable remissions in both trials, exceeding what many thought possible for an “off-the-shelf” approachstatnews.com.
3 November 2025
··
Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Illumina’s stock has whipsawed in late 2025. After drifting near its 52-week lows, it ticked up to the mid-$90s by mid-October 2025. Following the Oct. 30 earnings report, ILMN exploded higher: by Oct. 31 it was trading around $120 ts2.tech Marketbeat. TS2.tech notes that the stock was “around the high $110s–$120 range” on Oct. 31, a sharp jump from the mid-$90s “just days prior” ts2.tech. The surge was driven by the earnings beat and raised guidance. In one week ILMN recovered roughly 20–25% of its value ts2.tech ts2.tech. Despite the rally, the stock still trades below its Nov 2024 peak and its YTD performance is mixed. Daily trading volume and volatility have spiked as analysts and investors react to the news.
1 November 2025
···
Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Cabaletta’s stock has been very volatile. From ~$2.40 on Oct 27 it briefly dipped to the $2.47 area by Oct 30, then exploded higher on Oct 31. Benzinga notes that CABA “rose 36.6% to $3.38” intraday on Oct 31benzinga.com; it eventually closed at $3.61stockanalysis.com. Over the week of Oct 25–31, CABA gained ~37%tradingview.com. For perspective, its 52-week range is roughly $0.99–$5.46stockanalysis.com.
31 October 2025
··
Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Illumina’s latest quarterly report provided a much-needed spark for investors. The San Diego-based genomics giant reported $1.084 billion in revenue for Q3, slightly above Wall Street estimates and flat versus the same quarter last yearinvesting.com. While flat growth might not sound impressive, it exceeded Illumina’s own guidance range, marking an improvement in a year where demand had been soft. Adjusted earnings were $1.34 per share, handily beating the ~$1.17 consensusinvesting.com. CEO Jacob Thaysen noted the team “delivered Q3 results that exceeded the high-end of our guidance… driven by revenue acceleration in clinical, our largest market segment.”investing.com Clinical demand picked up nicely, helping offset weaker research academia sales.
31 October 2025
··
1 … 13 14 15 16 17 … 19
Go toTop